• Home
  • The MMS Difference
    • About Us
    • Leadership
    • Certifications
  • Services
    • Regulatory Affairs and Operations
    • Data Management and Biostatistics
    • Regulatory and Medical Writing
    • Drug Safety and Pharmacovigilance
    • Compliance and Transparency
    • Data Sciences
  • Working with MMS
  • News and Media
  • Webinars
  • MMS Blog
  • Careers
  • Contact Us
MMS
Ask the expert: Policy 0070 redaction packages suspended by EMA until 2019

Ask the expert: Policy 0070 redaction packages suspended by EMA until 2019

by Don McLean | Aug 2, 2018 | Blog

Ask the expert: Policy 0070 redaction packages suspended by EMA until 2019 by Staff writer Last week, the European Medicines Agency announced that as of August 2018, it would “temporarily scale back or suspend additional activities until at least September 2019.” This...

Recent Posts

  • Why COVID-19 testing devices require a high level of specificity
  • Whitepaper: Pharmaceutical Industry Challenges Facing Clinical Trial Disclosure and Transparency
  • Helping to Accelerate the Search for Solutions to the COVID-19 Crisis
  • IGY Life Sciences Partners with MMS Holdings to Develop Novel COVID-19 Antibody Treatment
  • Pharmaceutical Industry News Roundup: May 2020

Tags

ALZ awareness Alzheimers big data biosimilars biostatistics Clinical Development clinical research clinical study reports clinical trials clinical trial transparency Community Compliance COVID-19 CRO data management data privacy data science drug development EMA ENDALZ FDA Flint GDPR GXP auditing Health Analytics Collective Health Canada Lay summaries leadership medical writing NDA submission opioids pharma pharmacovigilance PhUSE Policy 0070 quality control real world data regulatory operations REMS resourcing statistical programming suicidality transparency trial regulation Volunteering